PSA - Quo vadis?;PSA - Quo vadis?

Urologe - Ausgabe A

Volumn 48, Issue 9, 2009, Pages 1008-1017

  Borgermann C ^a   Loertzer, H ^b   Luboldt, H J ^c   Hammerer, P ^d   Fornara, P ^e   Graefen, M ^f   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Klinikpraxis für Urologie   (Germany)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f Martini Klinik   (Germany)

Author keywords

Digital rectal examination (DRE); Early detection; Prostate cancer; Prostate specific antigen (PSA); PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DIGITAL RECTAL EXAMINATION; LIFE EXPECTANCY; MEDICAL LITERATURE; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

AMBULATORY CARE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 70349240236     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-2076-3     Document Type: Review

References (61)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17(2):159-163
2. Hoedemaeker RF, Rietbergen JB, Kranse R et al (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 164(2):411-415
3. Catalona WJ, Richie JP, Ahmann FR et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151(5):1283-1290
4. Luboldt HJ, Altwein JE, Bichler KH et al (1999) Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle. Urologe A 38(2):114-123
5. Statistisches Bundesamt (2009) http://www.desta-tis.de/basis/d/gesu/ gesutab20.php. Statistisches Bundesamt, Wiesbaden
6. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328
7. Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-1319
8. Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50(1 ):71-78
9. StameyTA,CaldwellM,McNeal JEetal (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?J Urol 172(4 Pt1):1297-1301
10. Brawer MK, Chetner MP (1997) In: Walsh PC, Retik A, StameyTA, Vaughan EJ (eds) Campell's urology. Saunders, Philadelphia, pp 2506-2518
11. Catalona WJ, Loeb S (2005) The PSA era is not over for prostate cancer. Eur Urol 48(4):541-545
12. Arbeitsgemeinschaft wissenschaftlich medizi-nischer Fachgesellschaften (2002) S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdia-gnostik (Früherkennung des Prostatakarzinoms). http://www.awmf-online.de
13. Bill-Axelson A, Holmberg L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144-1154
14. Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152(5 Pt2):1831-1836
15. Aus G, Hugosson J, Norlen L (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154(2 Pt 1):460-465
16. de Vries SH, Postma R, Raaijmakers R et al (2007) Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51(2):366-374 (Pubitemid 44937799)
17. D'amico AV, Whittington R, Malkowicz SB et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95(2):281-286
18. Bangma CH, Roemeling S, Schroder FH (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25(1 ):3-9
19. Montironi R, Mazzucchelli R, Santinelli A et al (2005) Incidentally detected prostate cancer in cystoprostatectomies: pathological and mor-phometric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol 36(6):646-654
20. Epstein JI, Potter SR (2001) The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 166(2):402-410
21. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56(2):106-130
22. Thompson IM, Goodman PJ, Tangen CM et al (2003)The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215-224
23. Gosselaar C, Roobol MJ, Schroder FH (2005) Pre-valenceand characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 95(2):231-237
24. Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172(5Pt2):S48-S50
25. Djavan B, Kadesky K, Klopukh B et al (1998) Glea-son scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 33(3):261-270
26. Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17(3):292-306
27. Koksal IT, Ozcan F, Kadioglu TC et al (2000) Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. Eur Urol 37(6):670-674
28. Pinthus JH, Witkos M, Fleshner NE et al (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176(3):979-984
29. Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16):2215-2220
30. Carter HB, Ferrucci L, Kettermann A et al (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21 ):1521-1527
31. Berger AP, Deibl M, Strasak A et al (2007) Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69(1):134-138
32. Raaijmakers R, Wildhagen MF, Ito Ket al (2004) Prostate-specific antigen change in the european randomized study of screening for prostate cancer, section rotterdam. Urology 63(2):316-320
33. Loeb S, Roehl KA, Catalona WJ, Nadler RB (2007) Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177(3):899-902 (Pubitemid 46223578)
34. Soletormos G, Semjonow A, Sibley PE et al (2005) Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51 (8):1342-1351
35. Stephan C, Klaas M, Muller C et al (2006) Inter-changeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52(1 ):59-64
36. Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level
37. Ulmert D, Serio AM, O'Brien MF et al (2008) Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 26(6):835-841
38. Punglia RS, Cullen J, Mcleod DG et al (2007) Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Cancer 110(9):1973-1978
39. D'amico AV (2008) Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer. J Clin Oncol 26(6):823-824
40. Etzioni RD, Ankerst DP, Weiss NS et al (2007) Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 99(20):1510-1515
41. Vickers AJ, Savage C, O'Brien MF, Lilja H (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27(3):398-403
42. Price CP, Allard J, Davies G et al (2001) Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programmefor prostate cancer. Ann Clin Biochem 38(Pt3):188-216
43. Oberpenning F, Hetzel S, Weining C et al (2003) Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol 43(5):478-484
44. Carter HB, Epstein JI, Chan DW et al (1997) Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277(18):1456-1460
45. Schröder FH, Raaijmakers R, Postma R (2005) 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 174(2):489-494
46. van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH (2003) Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95(19):1462-1466
47. Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343-346
48. Morgan TO, Jacobsen SJ, McCarthy WF et al (1996) Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335(5):304-310
49. Fang J, Metter EJ, Landis P et al (2001) Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58(3):411-416
50. Loeb S, Roehl KA, Antenor JA et al (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67(2):316-320
51. Ross KS, Carter HB, Pearson JD, Guess HA (2000) Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284(11):1399-1405
52. Carter HB, Epstein JI, Partin AW (1999) Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpal-pable disease. Urology 53(1):126-130
53. Smith CV, Bauer JJ, Connelly RR et al (2000) Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 164(6):1964-1967
54. Ries LA, Melbert D, Krapcho M (2008) SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://www.seer.cancer.gov/ csr/1975-2005/
55. Horan AH, McGehee M (2000) Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy. BJU Int 85(9):1063-1066
56. Johansson JE, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291 (22):2713-2719
57. Carter HB, Ferrucci L, Kettermann A et al (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a win-dow of curability. J Natl Cancer Inst 98(21):1521-1527
58. Bryant RJ, Hamdy FC (2008) Screening for prostate cancer: an update. Eur Urol 53(1):37-44
59. Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273(4):289-294
60. Stenman UH, Hakama M, Knekt P et al (1994) Serum concentrations of prostate specific antigen and its complexwith alpha 1-antichymotryp-sin before diagnosis of prostate cancer. Lancet 344(8937):1594-1598
61. Albertsen PC, Fryback DG, Storer BE et al (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156(1):127-132